This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|July 28, 2021
J.T.Baker Robotic Tips from Avantor Offer Precision Workflow
Author(s)BioPharm International Editors
Avantor’s newly unveiled J.T.Baker robotic tips is the latest in their line of automated precision plastics.
Advertisement
Avantor’s new J.T.Baker robotic tips, a series of robotic tips designed for use in robotic liquid handling and research workstations launched in July 2021, are designed for a range of applications, including genomics, cell biology, and proteomic workflows. They come in two formats: conductive and clear.
The conductive tips are designed to minimize downtime and keep operations running smoothly. Small liquid volumes can be sampled with high precision and without contamination. Additionally, the Hamilton and Tecan-type tips can be used in many robotic stations.
The clear tips are built for both sample preparation and drug discovery applications. Because these tips are transparent, users can visually recognize when the product is foaming for sampling purposes.
The J.T.Baker robotic tips are the latest in Avantor’s line of automated precision plastics, and one of the first to be announced following the company’s recent acquisition of Germany-based Ritter (and affiliates), a manufacturer of high-quality robotic and liquid handling consumables, including conductive pipette tips, in June 2021. Each batch is independently tested to make sure there are no contaminants such as DNase, RNase, amphipathic tail-anchoring peptide, and pyrogens.
“Our new, high-quality J.T.Baker robotic tips help researchers get the reliable, repeatable results required to keep critical life sciences work moving forward,” said Rohit Shroff, senior vice-president of Global Lab Products at Avantor, in a July 12, 2021 company press release. Our tips provide customers the precision and reliability they need to support their dynamic requirements.”
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5